1. Home
  2. WVE vs SHCO Comparison

WVE vs SHCO Comparison

Compare WVE & SHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • SHCO
  • Stock Information
  • Founded
  • WVE 2012
  • SHCO 1995
  • Country
  • WVE Singapore
  • SHCO United Kingdom
  • Employees
  • WVE N/A
  • SHCO N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • SHCO Hotels/Resorts
  • Sector
  • WVE Health Care
  • SHCO Consumer Discretionary
  • Exchange
  • WVE Nasdaq
  • SHCO Nasdaq
  • Market Cap
  • WVE 939.3M
  • SHCO 1.0B
  • IPO Year
  • WVE 2015
  • SHCO 2021
  • Fundamental
  • Price
  • WVE $6.35
  • SHCO $6.32
  • Analyst Decision
  • WVE Strong Buy
  • SHCO Strong Buy
  • Analyst Count
  • WVE 11
  • SHCO 3
  • Target Price
  • WVE $20.91
  • SHCO $7.50
  • AVG Volume (30 Days)
  • WVE 1.7M
  • SHCO 226.5K
  • Earning Date
  • WVE 05-08-2025
  • SHCO 05-09-2025
  • Dividend Yield
  • WVE N/A
  • SHCO N/A
  • EPS Growth
  • WVE N/A
  • SHCO N/A
  • EPS
  • WVE N/A
  • SHCO N/A
  • Revenue
  • WVE $104,939,000.00
  • SHCO $1,224,734,000.00
  • Revenue This Year
  • WVE N/A
  • SHCO $8.74
  • Revenue Next Year
  • WVE N/A
  • SHCO $5.04
  • P/E Ratio
  • WVE N/A
  • SHCO N/A
  • Revenue Growth
  • WVE N/A
  • SHCO 8.21
  • 52 Week Low
  • WVE $4.25
  • SHCO $4.43
  • 52 Week High
  • WVE $16.74
  • SHCO $8.47
  • Technical
  • Relative Strength Index (RSI)
  • WVE 40.37
  • SHCO 56.33
  • Support Level
  • WVE $5.62
  • SHCO $5.82
  • Resistance Level
  • WVE $7.07
  • SHCO $6.75
  • Average True Range (ATR)
  • WVE 0.60
  • SHCO 0.33
  • MACD
  • WVE 0.01
  • SHCO 0.07
  • Stochastic Oscillator
  • WVE 26.35
  • SHCO 59.81

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About SHCO Soho House & Co Inc.

Soho House & Co Inc is a membership platform of physical and digital spaces that connects a vibrant, diverse group of members from across the world. The members use the platform to work, socialize, connect, create, and flourish all over the world. It offers lease agreements for Houses, hotels, restaurants, studios, spas, and other properties. The company's reportable segments are: United Kingdom; The Americas; and Europe and Rest of the world. The majority of its revenue is generated from the Americas segment, which encompasses its operating units in the Americas, including Soho Houses, stand-alone U.S. restaurants, Soho Friends, and the management fees under a hotel management contract for the operation of The Ned London.

Share on Social Networks: